
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid Ltd is a clinical-stage biopharmaceutical company focused on developing its proprietary PLEX drug delivery technology, aiming to address surgical site infections through its flagship product, D-PLEX100, which has shown promising results in late-stage clinical trials. The recent agreement with shareholders will secure $26.7 million in funding, enabling the company to schedule a pre-NDA meeting with the FDA and potentially file for D-PLEX100's approval in the first half of 2026. This influx of capital, coupled with the positive efficacy observed in trials, positions PolyPid well for future growth and regulatory advancement.
Bears say
The analysis of PolyPid Ltd's financial outlook reflects concerns over the potential failure of its product candidates to deliver statistically significant results in clinical studies, which poses a substantial risk to the perceived value of the company. Furthermore, even if clinical trials are successful, there remains uncertainty regarding regulatory approvals from domestic and foreign agencies, which could further diminish the company's value. In addition, complications associated with patent procedures raise further concerns about potential revenue erosion that is anticipated to begin in 2036, contributing to an overall negative outlook on PolyPid's stock.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares